Quectel Releases New 4G/5G, LPWA and GNSS Antennas to Help Customers Optimize Device Performance
11.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, an IoT global solutions provider, proudly announces the launch of an exciting line-up of antennas designed to meet a wide spectrum of requirements:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711943901/en/
Quectel releases new 4G/5G, LPWA and GNSS antennas to help customers optimize device performance (Photo: Business Wire)
- YEMN926J1A: This state-of-the-art 9-in-1 5G screw mount combo antenna is at the forefront of technology. It offers superior performance for 5G networks and is designed with a screw mount for easy installation.
- YECW000N1A: This external antenna is specifically optimized for low power wide area (LPWA) networks. It provides excellent connectivity for LPWA applications and ensures reliable and efficient communication.
- YEGT000W8A: Our advanced active global satellite navigation system (GNSS) L1 and L5 antenna, ideal for precise positioning and timing. It offers enhanced accuracy and reliability for GNSS applications.
These antennas showcase cutting-edge technology and are designed to meet the demands of today's connectivity requirements.
“We’re proud to launch these three new antennas which further add to our range of 4G/5G, LPWA and GNSS antennas,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Antennas are often overlooked during device development but it’s important to enable developers with antennas that can be optimized for their specific use cases and provide them with the performance they need to meet their application needs. These new antennas provide customers with even greater opportunities to optimize their solutions as they build a smarter world.”
The YEMN926J1A is a 9-in-1 5G screw mount combo antenna optimized for 5G and 4G networks. It includes a GNSS antenna and measures 167mm x 57mm. Both RoHS and REACH compliant, the combo antenna also is IP67 and IP69K rated which means it offers complete protection against ingress of dust and airborne particles as well as protection against water and liquids up to and including immersion in up to 1m of water. The IP69K rating also means the product can withstand washdown pressure of 80-100 bar in phases of 14-16 l/min at temperatures of up to 80°C.
The ultra-wide-band 5G/4G antenna box provides broad coverage from 600-6,000MHz while offering support for 3G and 2G networks as well at Cat-M and NB-IoT. The antenna is designed to work with various ground plane sizes or in free space for ease of integration with nine cable connections on the antenna as required and cable length options from 300mm to 5000mm, terminated with SMA connectors. The screw mount omnidirectional antenna is easy to install with maximized durability and is compatible with Quectel's RM520x series modules.
The YECW000N1A external antenna offers high efficiency with a low profile and is optimized for LPWA connections. With dimensions of 149.73mm x 49.91mm x 35.5mm, the antenna operates in the 450-470MHz, 700-960MHz and 1710-2690MHz frequency bands. The external 4G antenna covers the main LTE bands and is also compatible with 3G, 2G and LPWA bands.
RoHS compliant, the YECW000N1A has been carefully designed so it is minimally influenced by the internal environment of devices it is connected to. This enables it to deliver better efficiency, radiation and gain while providing optimized performance for customers’ products. A further advantage is that Quectel offers flexible installation options with custom cable lengths and connectors available.
Completing Quectel’s latest antenna introductions, the YEGT000W8A is an active GNSS L1 and L5 antenna that supports the 1164-1189MHz and 1559-1606MHz frequency bands. With dimensions of 65mm x 45mm, the GNSS antenna is RoHS and IP67 compliant.
The YEGT000W8A offers a choice of configurations to guarantee the most suitable polarization type and was specifically developed for 5G RAN timing. Quectel’s positioning products support single-band or multi-band operation modes to meet various high- precision positioning requirements of customers’ products. Customized connector types and cable lengths are provided according to customers’ requirements.
In addition to providing antennas, Quectel also provides comprehensive antenna design support which includes simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. This support, allied to innovative antennas, helps enable customers to optimize device performance.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711943901/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom